*Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital Aarau, Aarau, Switzerland; †Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland; ‡Clinic for Infectious Diseases, University Hospital Berne, University of Berne, Berne, Switzerland; §Division of Infectious Diseases and Hospital Epidemiology, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland; ‖Division of Infectious Diseases and Hospital Epidemiology, University Hospital Geneva, University of Geneva, Geneva, Switzerland; ¶Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland; #Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; **Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland; and ††Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):472-8. doi: 10.1097/QAI.0b013e3182a61ea9.
Alcohol consumption may affect the course of HIV infection and/or antiretroviral therapy (ART). The authors investigated the association between self-reported alcohol consumption and HIV surrogate markers in both treated and untreated individuals.
Prospective cohort study.
Over a 7-year period, the authors analyzed 2 groups of individuals in the Swiss HIV Cohort Study: (1) ART-naïve individuals remaining off ART and (2) individuals initiating first ART. For individuals initiating first ART, time-dependent Cox proportional hazards models were used to assess the association between alcohol consumption, virological failure, and ART interruption. For both groups, trajectories of log-transformed CD4 cell counts were analyzed using linear mixed models with repeated measures.
The authors included 2982 individuals initiating first ART and 2085 ART naives. In individuals initiating first ART, 241 (8%) experienced virological failure. Alcohol consumption was not associated with virological failure. ART interruption was noted in 449 (15%) individuals and was more prevalent in severe compared with none/light health risk drinkers [hazard ratio: 2.24, 95% confidence interval: 1.42 to 3.52]. The association remained significant even after adjusting for nonadherence. The authors did not find an association between alcohol consumption and change in CD4 cell count over time in either group.
No effect of alcohol consumption on either virological failure or CD4 cell count in both groups of ART-initiating and ART-naive individuals was found. However, severe drinkers were more likely to interrupt ART. Efforts on ART continuation should be especially implemented in individuals reporting high alcohol consumption.
饮酒可能会影响 HIV 感染和/或抗逆转录病毒治疗(ART)的进程。作者研究了报告的饮酒量与治疗和未治疗个体的 HIV 替代标志物之间的关联。
前瞻性队列研究。
在 7 年期间,作者分析了瑞士 HIV 队列研究中的 2 组个体:(1)未接受 ART 的 ART 初治个体,(2)开始首次 ART 的个体。对于开始首次 ART 的个体,使用时间依赖性 Cox 比例风险模型评估饮酒、病毒学失败和 ART 中断与饮酒之间的关联。对于这两组个体,使用具有重复测量的线性混合模型分析对数转换 CD4 细胞计数的轨迹。
作者纳入了 2982 名开始首次 ART 的个体和 2085 名 ART 初治个体。在开始首次 ART 的个体中,有 241 名(8%)发生病毒学失败。饮酒与病毒学失败无关。449 名(15%)个体发生了 ART 中断,在严重饮酒者中比在无/轻度健康风险饮酒者中更为常见[风险比:2.24,95%置信区间:1.42 至 3.52]。即使在调整了不依从性后,该关联仍然显著。作者在两组开始 ART 和未开始 ART 的个体中均未发现饮酒与 CD4 细胞计数随时间变化之间存在关联。
在开始 ART 和未开始 ART 的个体中,饮酒对病毒学失败或 CD4 细胞计数均无影响。然而,重度饮酒者更有可能中断 ART。应特别针对报告高饮酒量的个体实施 ART 持续治疗的措施。